A Phase 1, Dose Escalation Study to Assess the Safety and Tolerability of ASP9853 With Either Docetaxel or Paclitaxel in Patients With Advanced Non-hematologic Malignancies

ClinicalTrials.gov ID: NCT01705483

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01705483. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, Multicenter, Open-Label, Dose Escalation Study of ASP9853 in Combination With Either Docetaxel or Paclitaxel in Subjects With Advanced Non-hematologic Malignancies

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine the safety and tolerability and pharmacokinetics of ASP9853 combined with docetaxel or with paclitaxel in subjects with advanced non-hematologic malignancies.

Study identification

NCT ID: NCT01705483
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 1
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Enrollment: 21 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 28, 2012 (Actual)
Primary completion: Jun 11, 2014 (Actual)
Completion: Jun 11, 2014 (Actual)
Last update posted: Nov 7, 2024

2012 – 2014

United States locations

U.S. sites: 4
U.S. states: 3
U.S. cities: 3

Facility	City	State	ZIP	Site status
Beth Israel Deaconess Medical Center	Boston	Massachusetts	02215	—
Dana Farber Cancer Institute	Boston	Massachusetts	02215	—
Barbara Ann Karmanos Cancer Center	Detroit	Michigan	48201	—
Sarah Cannon Research Institute	Nashville	Tennessee	37203	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01705483, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Nov 7, 2024 · Synced Nov 14, 2026